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Abstract
Purpose Cancer-related fatigue (CRF) is frequently over-
looked. Adherence to treatment guidelines may be related
to the patient’s views about illness. This study aimed at
exploring patients’ views about CRF and determining
whether they are congruent with best practice treatments.
Methods Data were collected in 160 consecutive patients
hospitalized in a supportive care setting. Biological,
clinical, and psychological variables were assessed using
validated questionnaires. Patients were also asked to
complete the Brief Fatigue Inventory (BFI) and a question-
naire investigating their main symptoms and views about
CRF and its management.
Results Patients were mainly men (60%); median age was
66 years. Various cancer diagnoses were represented; 17.5%
had primary local diseases, 40% local recurrences, and
42.5% metastatic diseases. The majority of the patients
experienced moderate or severe CRF (76.3%) on the BFI.
Fatigue was the most frequently reported symptom (87.5%).
Only anxiety, depression, and dimensions of quality of life
were significantly related with CRF. Two thirds of the
patients associated CRF with cancer-related morbidities. As
for the best treatments, patients first stressed control of
adverse effects. Over half of the patients were reluctant to
report fatigue, mainly because they considered fatigue as an
unavoidable side effect, but also because they feared a
change towards less active/aggressive treatments.
Conclusion Patients mostly consider that CRF must be
tolerated. Guidelines emphasize activity enhancement strat-
egies as beneficial. The patients’ preferences for rest rather
than activity may be related to their high level of fatigue,
which leads them to disregard activity as a possible
treatment.
Keywords Fatigue . Cancer-related fatigue .
Supportive care . Patients’ views . Treatment preferences .
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Introduction
Cancer-related fatigue (CRF) is defined as a persistent,
subjective sense of weakness and tiredness, despite ade-
quate rest, that interferes with usual functioning [1, 2].
However, there is no clear agreement on a scientifically
based definition largely because the exact mechanisms
causing fatigue are still in the early stages of investigation.
A variety of mechanisms have been proposed for CRF,
although none has been proven [3]. Physiological and
psychosocial factors are recognized as playing a part [4, 5].
Contributors to fatigue cover a wide range of causes,
including treatable conditions such as anemia, functional
deconditioning, and adverse effects of treatments as well as
other symptoms such as pain and depression [5].
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CRF is a common problem for patients who are
undergoing cancer treatment [6]. The true incidence of
CRF is difficult to ascertain. Published studies are restricted
to prevalence data. Estimates are that CRF affects between
17% and 90% of cancer patients overall [7–9]. More than
75% of the patients with advanced cancer are affected [8].
Furthermore, CRF has been described as a distressing
symptom, even more than pain or nausea and vomiting
[10]. Although CRF is identified by patients as a distressing
symptom associated with cancer and its treatment, it is
often overlooked as a potentially treatable problem [5, 11].
However, systematic reviews have shown the effectiveness
of various interventions, pharmacological [12], physical via
exercise [13], or psychosocial [14].
The clinical guidelines of the National Institutes of
Health and the National Comprehensive Cancer Network
(NCCN) put a major emphasis on the various aspects of the
prevention and treatment of CRF [1, 2]. Management of
CRF involves the assessment and the treatment of contrib-
uting factors (e.g., treating anemia, managing pain, or
depression) resulting in specific pharmacological or non-
pharmacological interventions (e.g., education, counseling,
and exercise). However, the effective implementation of
these clinical guidelines is difficult. Various studies suggest
that adherence to treatment and recommendations is related
to the patient’s beliefs and expectations about illness and its
management [15–17]. From the patient’s perspective, non-
adherence may be a more rational decision, based on his/
her beliefs and previous experiences, than an irrational act
of noncompliance [15]. This decision is dependent on the
patient’s weighing of the balance between his/her percep-
tion of the costs and benefits of the intervention. In this
process, the doctors’ point of view and the scientific
evidence are not the only sources of information [18], and
the personal and social circumstances within which they
live play a crucial role in the patient’s decision making.
Agreement between the patients’ views and the guidelines
may thus be a crucial issue, insofar as the patients’ beliefs
and experiences about CRF may not be congruent with best
practice treatments recommended in the guidelines. This is
of special interest when it comes to enhancing the practical
utility of these guidelines for the patients.
This study aimed to quantify and qualify CRF in
hospitalized patients, to investigate patients’ views about
CRF, and to determine as to what extent patients’ views are
congruent with the best practice treatments described in the
guidelines.
Methods
Setting The study was conducted at a cancer supportive
care unit. This 12-bed facility is part of the Division of
General Medical Rehabilitation of the Geneva University
Hospitals, a 96-bed internal subacute medical ward devoted
to general medical rehabilitation and supportive care in
cancer. The multidisciplinary staff of the supportive care
unit is headed jointly by an oncologist and an internist.
Consecutive cancer patients hospitalized in the supportive
care unit during an 18-month period were investigated in
the first 48 h of their admission. Inclusion criteria were
patients ≥18 years old, undergoing an active cancer
treatment and a sufficient knowledge of French to partic-
ipate in the study. The study protocol was approved by the
hospital Ethics Committee, and the study was performed in
accordance with the ethical standards of the Declaration of
Helsinki. All included patients gave their written informed
consent.
Materials The Brief Fatigue Inventory (BFI) [19], specif-
ically developed to measure fatigue in cancer populations,
was used; this nine-item scale is user-friendly, and its
psychometric properties have been well established [20].
The first three items deal with feelings of fatigue (right
now, usual level, and worst level) over the past 24 h. These
three items are numerical rating scales (NRS) graded from 0
(“no fatigue”) to 10 (“as bad as you can imagine”). The
next six items deal with various activities of daily living,
relationships, or quality of life experienced over the
previous 24 h. These six items are also NRS graded from
0 (“does not interfere”) to 10 (“completely interferes”). A
global index is then calculated by adding the scores of the
nine items and dividing the sum by nine, for a final score
comprised between 0 and 10. Level 0 indicates no fatigue;
levels 1–3 indicate mild fatigue; levels 4–6, moderate
fatigue; and levels 7–10, severe fatigue [20].
In addition, a five-item questionnaire was devised to
evaluate the patients’ perception of their main symptoms
and impact on everyday life as measured on 11-point NRS,
as well as the presence and type of problems related to the
report of fatigue; the questionnaire also included the
investigation of the patients’ views about causes of fatigue
and best/expected treatments. The multiple choice questions
about causes and treatment of CRF were devised using the
various domains of recommendations described as best
evidence in the practice guidelines [1, 2]. The questionnaire
was pretested on a subset of patients. The physicians’
identification of the main symptoms of the patients on
admission was compared to the patients’ appraisal. This
identification is routinely performed by the physicians in
charge of the unit on the basis of the same items as those
used in the patient questionnaire.
Along with these fatigue-specific measurements, other
data were collected to allow for the characterization of the
patients and of their disease and treatments. A comorbidity
index (Charlson et al. [21]), laboratory data (hemoglobin
364 Support Care Cancer (2011) 19:363–370
levels and serum biochemical variables), type and stage of
cancer (primary local diseases, local recurrences, or
metastatic diseases), chemotherapy and radiotherapy in the
last 3 months, and medication intake at the time of the
admission (analgesics, corticosteroids, antiemetics, anticon-
vulsants, antidepressants, and benzodiazepines) were
extracted from the medical charts. Validated scales were
used to assess functional status and health-related quality of
life (Eastern Cooperative Oncology Group (ECOG) perfor-
mance status [22], European Organisation for Research and
Treatment of Cancer (EORTC)-Quality of Life Question-
naire for Cancer patients (QLQC)-30 [23]), as well as
anxiety and depression (Hospital Anxiety and Depression
Scale (HADS) [24, 25]).
Statistical methods Demographic and questionnaire data
were analyzed using Chi-square tests for categorical data
and t tests for continuous data. Pearson’s correlation was
used to compare BFI scores and clinical, psychosocial, and
functional scales.
Results
Patient inclusion During the study period, 228 patients
were recruited; 68 patients could not give an informed
consent (poor fluency in French [N=16]; cognitive impair-
ments [N=14]), or refused to participate [N=38]). Thus,
160 patients were included (Table 1); age ranged from 21 to
91 years old, with median age of 66 years.
Clinical characteristics of the patients A wide range of
cancer diagnoses were represented (Table 1); 28 patients
(17.5%) suffered primary local diseases, 65 (40%) local
recurrences, and 67 (42.5%) metastatic diseases. Mean time
since diagnosis was 1.5 years (range=0–12 years). Mean
Charlson comorbidity index was 7.48 (SD=1.9). Mean
hemoglobin level was 10.98 g/l (SD=1.6), and 21.9% of
the patients had a hemoglobin level <10 g/l, indicating a
moderate anemia. Patients had received various oncological
treatments in the previous 3 months. Most of the patients
were on analgesics, and a vast majority received benzodia-
zepines (Table 2). The vast majority of the patients (>80%)
experienced functional limitations as assessed by the ECOG
performance status. Similarly, the scores were low on the
physical and role functioning subscales of the EORTC-
QLQC-30. Nearly a third of the patients showed signs of
psychiatric morbidity on the HADS (Table 1).
Prevalence and impact of fatigue and other symptoms The
results of the BFI indicated that very few patients reported
no fatigue (N=19; 11.9%) or mild fatigue (N=19; 11.9%),
whereas moderate and severe fatigue were reported by 70
(43.8%) and 52 (32.5%) patients, respectively.
On admission, patients were questioned about their main
symptoms. They reported a mean of 3.8 symptoms/patient
(SD=1.8); the most frequent were fatigue (N=140; 87.5%),
pain (N=72; 45%), loss of appetite (N=62; 38.8%), sadness
or anxiety (N=61; 38.1%), and dyspnea (N=57; 35.6%). The
estimated mean impact of these symptoms was low for most
of these symptoms except for fatigue, however. Indeed, on a
0 to 10 NRS, the impact ranged from 1.89 to 2.21, except for
fatigue, which had a mean score of 5.8 (SD=3). Not
surprisingly, the patients’ perception of the impact of fatigue
was highly correlated with the BFI (Pearson r=0.923;
p<0.0001).
Bivariate correlations showed that among various
clinical characteristics of the patients (e.g., stage of the
disease, medication intake, and functional status), only
anxiety and depression as well as self-reported functional
scales and global evaluation of the quality of life were
significantly related with fatigue as measured by the BFI
(Table 2).
Patients’ views on the causes and best treatments of
fatigue Two thirds of the patients associated CRF with
cancer-related morbidities and treatments, in particular,
chemotherapy, radiotherapy, and surgery (Table 3). Among
the main CRF contributing factors described in the guide-
lines, one third of the patients pointed to muscle loss, sleep
disturbance, nutrition, and emotional distress, whereas
physical activity and anemia were only rarely mentioned.
Only one patient declared to have no opinion regarding the
factors contributing to CRF. As for the best treatments of
CRF, patients first stressed treatments aimed to control
adverse effects of chemo- and radiotherapy, and to handle
pain (two fifth of the patients); one third of them also
mentioned managing nutritional deficiencies, pharmacolog-
ical sleep therapy, and counseling for emotional distress; a
similar proportion of patients (one fourth) suggested bed
rest and progressive physical activity as best treatments for
CRF (Table 3). Only few patients cited psychostimulants
and pacing activities in the everyday life or during the
hospital stay. None of these responses was significantly
associated with the level of fatigue as measured by the BFI,
except for managing nutritional deficiencies, which was
significantly (p<0.01) more often mentioned by severely
fatigued patients (BFI≥7).
Fatigue in the patient–physician communication The vast
majority of the patients reported moderate or even severe
fatigue with a high impact (5.8 on an 11-point NRS) on
everyday life. However, the investigation of the presence
and type of problems possibly related to the report of
fatigue in the five-item questionnaire showed that 90
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Table 1 Sociodemographic, clinical, and psychological characteristics of the patients
N (%) Median (range)
Age 66 (21–91)
Gender
Men 96 (60)
Women 64 (40)
Education
Completed elementary school 31 (19.4)
Completed high school 95 (59.4)
Completed university 34 (21.3)
Charlson comorbidity index 7 (4–15)
Primary cancer site
Lung 41 (25.6)
Gastrointestinal 30 (18.8)
Head and neck 18 (11.3)
Urogenital 17 (10.6)
Breast 13 (8.1)
CNS 8 (5)
Hematological 6 (3.8)
Other 16 (10)
Oncological treatment before inclusion (<3 months)
Chemotherapy 72 (45.3)
Radiotherapy 48 (30.2)
Surgery 45 (28.3)
Hormonotherapy 23 (14.5)
Immunotherapy 7 (4.4)
Medication intake (admission)
Level I—acetaminophen 146 (91.3)
Level II—NSAIDs, weak opioids 57 (35.6)
Level III—strong opioids 88 (55)
Corticosteroids 125 (78.1)
Antiemetics 71 (44.4)
Antidepressants 23 (14.4)
Benzodiazepines 129 (80.6)
Fatigue score [BFI]
No fatigue 19 (11.9%)
Mild fatigue 19 (11.9%)
Moderate fatigue 70 (43.8%)
Severe fatigue 52 (32.5%)
Functional and emotional status
Functional status [performance status] 1 (0.6)
0=fully active 22 (14.0)
1=slightly impaired 73 (46.5)
2=up and about >50% 55 (35.0)
3=confined to bed >50% 6 (3.8)
4=totally disabled
Functional scales [EORTC-QLQC-30]
Physical functioning 40.0 (0–100)
Role functioning 33.3 (0–100)
Emotional functioning 66.7 (0–100)
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patients (56.3%) also reported to be uncertain whether to
discuss fatigue with the physician. The main reasons for
this reluctance were that they assumed that CRF is
unavoidable or a necessary adverse effect of cancer-
related treatment (43% and 36% of responses, respectively),
but they also stressed that they feared that their treatment
Fatigue—Brief Fatigue Inventory
Charlson 0.058
Performance status 0.087
Hemoglobin <10 g/l 0.04
Stage of disease
Primary local disease
Local recurrence
Metastatic disease
Time since Ca diagnosis −0.14
Prior oncological treatment (<3 months)
Chemotherapy 2.664
Radiotherapy 6.024
Surgery 0.640
Medication use (admission)
Antalgic level II 1.927
Antalgic level III 0.785
Corticosteroids 2.818
Antidepressants 7.846*
Benzodiazepines 3.223
Self-reported main symptoms (admission)
Fatigue 0.923**
Pain −0.068
Loss of appetite 0.129
Dyspnea 0.032
Emotional distress 0.004
EORTC-QLQ-C30
Physical functioning 0.158*
Role functioning 0.205*
Emotional functioning 0.029
Cognitive functioning 0.049
Social functioning 0.179*
Global quality of life 0.219*
Fatigue (symptom subscales) 0.374*
HADS anxiety 0.205*
HADS depression 0.290**
HADS total 0.266**
Table 2 Correlations between
fatigue (Brief Fatigue Invento-
ry) and clinical characteristics
*Pearson correlation coefficient
p value <0.05 (two-tailed)
**Pearson correlation coeffi-
cient p value <0.01 (two-tailed)
Table 1 (continued)
N (%) Median (range)
Cognitive functioning 66.7 (0–100)
Social functioning 58.3 (0–100)
Global QoL 58.3 (0–100)
Emotional status [HADS] (N=123)
Anxiety score≥11 41 (33.3) 9 (0–17)
Depression score≥11 37 (30.1) 8 (0–19)
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may be altered if they reported fatigue (41%). The
responses also showed that patients tended to believe that
there is no treatment for CRF (28%) and that they may
bother the physician with fatigue complaints (26%);
furthermore, 26% of them indicated that physicians do not
tackle this issue and/or that they preferred to discuss it with
other health care providers (23%). Finally, 33% of the
patients indicated that they felt reluctant to discuss fatigue
with the physician but for no specific reason.
The comparison of the patients’ appraisal of their main
symptoms with the physicians’ evaluation of the main
symptoms of the patients on admission showed varying levels
of agreement: the patients and the physicians of the supportive
care unit agreed on the presence (or absence) of fatigue in
59.7% of the cases; fatigue was mentioned in 87.5% of the
patients, whereas it was mentioned as a main symptom in 56%
of the cases by the physician in charge. The agreement was
57.2% for sadness or anxiety and higher for loss of appetite
(62.3%), pain (65%), and dyspnea (75.5%).
Discussion
The vast majority of the patients in this study experienced
moderate or severe CRF. The impact of CRF was described as
clearly more important than other self-reported symptoms,
such as pain, loss of appetite, sadness or anxiety, and dyspnea.
Despite the importance of fatigue, more than half of patients
were reluctant to discuss it with the physician, mainly because
they considered fatigue as an unavoidable side effect of both
the disease and its treatment, but also because they feared a
change toward a less active/aggressive treatment to accom-
modate fatigue.
The results of our study put a strong emphasis on the
patient’s weighing of the perceived costs and benefits not
only of the interventions but also of discussing fatigue.
These beliefs may act as barriers to communication about
fatigue [15, 18]. Fatalistic attitudes about possible treatment
of CRF have been stressed [11], and studies also suggest
that the physicians often fail to recognize fatigue as a
significant problem for the patient [11, 26, 27]. In line with
this, our results indicate that hardly more than half of the
physicians’ and the patients’ responses converged on
fatigue as a main symptom, whereas it was mentioned as
such in almost 90% of the patients.
It is noteworthy that all the patients had views to express
about the reasons for CRF and the expected/best treatments.
Responses encompassed representations of fatigue in terms
of physical exhaustion, leading to solutions aiming at
“recharging the battery” by eating, resting, and sleeping.
Fatigue is a commonplace symptom and has highly varying
degrees of severity; it comprises perceptions as diverse as
“healthy fatigue” and CRF. This variety of perceptions
refers both to physical sensations and to affective experi-
ences. The affective component is not only determined by
the sensation itself but also by the context: e.g., “feeling
dead” may refer to the well-being related to what is
commonly labeled a healthy fatigue due to (pleasant)
physical activities. This attempt to “recharge the battery”
and sort out the perceived physical and affective experi-
ences of fatigue may contribute to the patients’ difficulty to
consider the recommendations regarding physical activity.
The NCCN guidelines for CRF [1, 2] emphasize activity
enhancement and energy conservation strategies as benefi-
cial interventions for CRF. These strategies did not meet the
patients’ preferences, however. The patients’ preference for
bed rest and pharmacological sleep therapy rather than
Table 3 Patients’ assessment of the factors contributing to cancer-related fatigue (CRF) and of best/expected treatments for CRF
Assessment N (%)a Treatment N (%)a
Cancer-related morbidities, “cancer itself” 108 (67.5) Treating AE of cancer-related treatments 69 (43.1)
Cancer-related treatments (chemo-, radiotherapy,
and surgery)
100 (62.5) Pain management 62 (38.8)
Loss of muscles 60 (37.5) Managing nutritional deficiencies 51 (31.9)
Sleep disturbance 55 (34.4) Sleep therapy (pharmacological) 49 (30.6)
Nutrition 48 (30) Counseling for emotional distress 48 (30)
Emotional distress 46 (28.8) Bed rest 44 (27.5)
Pain 37 (23.1) Progressive physical activity 41 (25.6)
Non cancer-related morbidities 22 (13.8) Complementary medicine 38 (23.8)
Physical activity 21 (13.1) Psychostimulants 22 (13.8)
Anemia 12 (7.5) Planning of hospital stay (care, consultations, rest, exercises…) 13 (8.1)
Others 1 (0.6) Prioritizing and pacing daily life activities 7 (4.4)
I have no opinion 1 (0.6) Others 3 (1.9)
a As more than one response was possible, the total is higher than 100%
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progressive physical activity may be related to their high
level of fatigue. Similarly, recommendations about priori-
tizing and pacing activities during the hospital stay or in
everyday life were also overlooked.
Besides the frequent attribution of fatigue to cancer and
its treatment, patients also pointed to causes identified as
treatable contributing factors by the NCCN guidelines, in
particular, nutrition, muscle loss, sleep disturbance, and
emotional distress, but to a much lesser extent. According-
ly, managing nutritional deficiencies, pharmacological sleep
therapy, and counseling for emotional distress were selected
by the patients as the treatments they would rate best for
themselves.
Clinically, symptoms such as pain, loss of appetite and
dyspnea, or hemoglobin levels, were not correlated to
fatigue, contrary to the results of other studies [28–31].
There was no correlation either with medication intake
except for antidepressants. The relation between antide-
pressants and fatigue was probably mediated by anxiety,
and depression as the indication for antidepressants in these
patients was mainly depression and not other reasons such
as pain for example. Various clinical and psychological
characteristics were correlated with fatigue, but they did not
refer to the status of the disease or to comorbidities but
rather to the patient’s evaluation of his/her distress and
health-related quality of life. In the same line, fatigue was
not correlated with the functional status as assessed by the
care providers (ECOG performance status) but with the
self-reported functional scales of quality of life question-
naire (EORTC-QLQ-C30). These results are congruent with
other studies on the importance of psychological distress as
a correlate of fatigue [32–34].
This study has limitations. It has been conducted in a
teaching hospital, and it raises the question of the extent to
which the results can be generalized to other settings.
However, the clinical and psychological characteristics of
the patients in our sample were similar to those of other
supportive care settings [28]. Furthermore, the prevalence
and severity of fatigue were comparable to the data obtained
in other studies [4, 31]. This study is cross-sectional and
does not allow establishing causal relationships.
CRF is a highly complex symptom both from the
perspective of scientific and lay knowledge. Guidelines
may take physician focus away from the patient’s specific
experience [35, 36] including patients’ preferences about
treatment. The results of this study emphasize the role of
the health professionals in decoding the patients’ fears and
needs. It is difficult to talk about fatigue if it means a risk to
get a less active treatment; it is difficult to recommend
activity and movement if fatigue is associated with “too
much”: too much energy devoted to coping with the
disease, its treatments, and adverse effects, too many fears
that the disease is accelerating or that treatments might be
withdrawn. Clearly, the information patients need is not
(only) the information provided in the guidelines or in the
consent forms.
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